Q2 2021
Released Aug 5, 2021, before the open
10-Q filed Aug 5, 2021, 36 days after period end · 0001493152-21-018675
Q2 2021 · 10-Q
Revenue—
Net Income-$6.81M-$6.81M N/M vs Q2 2020N/M vs Q1 2021
EPS Diluted-$0.08-$0.08 N/M vs Q2 2020N/M vs Q1 2021
Operating Income-$2,990,279N/M
Operating Cash Flowderived-$2,363,282N/M
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q2 2021 | Q2 2020 | Q2 2019 | Q2 2018 |
|---|---|---|---|---|
| Revenue | — | — | $0.00 | $0.00 |
| Net Income | -$6.81M | -$6.37M | -$3.43M | -$3.26M |
| EPS Diluted | -$0.08 | -$0.13 | -$0.14 | -$0.15 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lipocine Inc. · CIK 1535955 · Engraved from SEC EDGAR